Cargando…

Relationship between thrombospondin-1, endostatin, angiopoietin-2, and coronary collateral development in patients with chronic total occlusion

This study is aimed to investigate whether serum angiostatic factors (thrombospondin-1 [TSP-1] and endostatin) or angiogenic factors (angiopoietin-2 [Ang-2]) are related to coronary collateral vessel development in patients with chronic total occlusion (CTO). A total of 149 patients were enrolled in...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Qing, Qian, Juying, Ma, Jianying, Ge, Lei, Ge, Junbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5370801/
https://www.ncbi.nlm.nih.gov/pubmed/27537575
http://dx.doi.org/10.1097/MD.0000000000004524
_version_ 1782518299710455808
author Qin, Qing
Qian, Juying
Ma, Jianying
Ge, Lei
Ge, Junbo
author_facet Qin, Qing
Qian, Juying
Ma, Jianying
Ge, Lei
Ge, Junbo
author_sort Qin, Qing
collection PubMed
description This study is aimed to investigate whether serum angiostatic factors (thrombospondin-1 [TSP-1] and endostatin) or angiogenic factors (angiopoietin-2 [Ang-2]) are related to coronary collateral vessel development in patients with chronic total occlusion (CTO). A total of 149 patients were enrolled in the study, and 39 patients with coronary artery disease but without significant stenosis were included in control group. In 110 patients with CTO lesion, 79 with Rentrop grades 2 to 3 collaterals were grouped as good collateral, while 31 with Rentrop grades 0 to 1 collaterals were grouped as poor collateral. Serum TSP-1, endostatin, and Ang-2 levels were studied. Serum endostatin level was significantly higher in poor collateral group compared with control group and good collateral group, respectively (96.2 ± 30.4 vs 77.8 ± 16.5 ng/mL, P = 0.007; 96.2 ± 30.4 vs 81.2 ± 30.4 ng/mL, P = 0.018). In multivariate analysis, decreased serum endostatin level was independently related to good coronary collateral development. Serum TSP-1 level was lower in patients with CTO compared with control group. However, no difference in TSP-1 level was detected between poor and good collateral group. The serum Ang-2 level did not show a significant difference among 3 groups. Circulatory endostatin may be a useful biomarker for coronary collateral development and potential target for therapeutic angiogenesis in patients with CTO.
format Online
Article
Text
id pubmed-5370801
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-53708012017-03-31 Relationship between thrombospondin-1, endostatin, angiopoietin-2, and coronary collateral development in patients with chronic total occlusion Qin, Qing Qian, Juying Ma, Jianying Ge, Lei Ge, Junbo Medicine (Baltimore) 3400 This study is aimed to investigate whether serum angiostatic factors (thrombospondin-1 [TSP-1] and endostatin) or angiogenic factors (angiopoietin-2 [Ang-2]) are related to coronary collateral vessel development in patients with chronic total occlusion (CTO). A total of 149 patients were enrolled in the study, and 39 patients with coronary artery disease but without significant stenosis were included in control group. In 110 patients with CTO lesion, 79 with Rentrop grades 2 to 3 collaterals were grouped as good collateral, while 31 with Rentrop grades 0 to 1 collaterals were grouped as poor collateral. Serum TSP-1, endostatin, and Ang-2 levels were studied. Serum endostatin level was significantly higher in poor collateral group compared with control group and good collateral group, respectively (96.2 ± 30.4 vs 77.8 ± 16.5 ng/mL, P = 0.007; 96.2 ± 30.4 vs 81.2 ± 30.4 ng/mL, P = 0.018). In multivariate analysis, decreased serum endostatin level was independently related to good coronary collateral development. Serum TSP-1 level was lower in patients with CTO compared with control group. However, no difference in TSP-1 level was detected between poor and good collateral group. The serum Ang-2 level did not show a significant difference among 3 groups. Circulatory endostatin may be a useful biomarker for coronary collateral development and potential target for therapeutic angiogenesis in patients with CTO. Wolters Kluwer Health 2016-08-19 /pmc/articles/PMC5370801/ /pubmed/27537575 http://dx.doi.org/10.1097/MD.0000000000004524 Text en Copyright © 2016 the Author(s). Published by Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle 3400
Qin, Qing
Qian, Juying
Ma, Jianying
Ge, Lei
Ge, Junbo
Relationship between thrombospondin-1, endostatin, angiopoietin-2, and coronary collateral development in patients with chronic total occlusion
title Relationship between thrombospondin-1, endostatin, angiopoietin-2, and coronary collateral development in patients with chronic total occlusion
title_full Relationship between thrombospondin-1, endostatin, angiopoietin-2, and coronary collateral development in patients with chronic total occlusion
title_fullStr Relationship between thrombospondin-1, endostatin, angiopoietin-2, and coronary collateral development in patients with chronic total occlusion
title_full_unstemmed Relationship between thrombospondin-1, endostatin, angiopoietin-2, and coronary collateral development in patients with chronic total occlusion
title_short Relationship between thrombospondin-1, endostatin, angiopoietin-2, and coronary collateral development in patients with chronic total occlusion
title_sort relationship between thrombospondin-1, endostatin, angiopoietin-2, and coronary collateral development in patients with chronic total occlusion
topic 3400
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5370801/
https://www.ncbi.nlm.nih.gov/pubmed/27537575
http://dx.doi.org/10.1097/MD.0000000000004524
work_keys_str_mv AT qinqing relationshipbetweenthrombospondin1endostatinangiopoietin2andcoronarycollateraldevelopmentinpatientswithchronictotalocclusion
AT qianjuying relationshipbetweenthrombospondin1endostatinangiopoietin2andcoronarycollateraldevelopmentinpatientswithchronictotalocclusion
AT majianying relationshipbetweenthrombospondin1endostatinangiopoietin2andcoronarycollateraldevelopmentinpatientswithchronictotalocclusion
AT gelei relationshipbetweenthrombospondin1endostatinangiopoietin2andcoronarycollateraldevelopmentinpatientswithchronictotalocclusion
AT gejunbo relationshipbetweenthrombospondin1endostatinangiopoietin2andcoronarycollateraldevelopmentinpatientswithchronictotalocclusion